Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Nineteen patients (2.5%) developed t-MDS or t-AML at a median follow-up of 4.4 years (range, 0 to 9.3). These malignancies were diagnosed at a median of 5.6 years (range, 1.4 to 13.9) after the diagnosis of NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy. The annualized rates were 0.3% per year after the diagnosis of NHL and 0.7% per year after treatment. Most patients with t-MDS or t-AML had multiple cytogenetic aberrations, commonly on chromosomes 5 and 7, suggesting an association with previous exposure to chemotherapy. CONCLUSION:
|
Authors | Myron S Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E Witzig, Leo I Gordon, Stephen Revell, Katie Vo, Arturo Molina |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 25
Issue 27
Pg. 4285-92
(Sep 20 2007)
ISSN: 1527-7755 [Electronic] United States |
PMID | 17709799
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Yttrium Radioisotopes
- ibritumomab tiuxetan
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Female
- Humans
- Leukemia, Myeloid, Acute
(complications, etiology)
- Lymphoma, Non-Hodgkin
(therapy)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(complications, etiology)
- Radioimmunotherapy
(methods)
- Treatment Outcome
- Yttrium Radioisotopes
(administration & dosage, adverse effects)
|